Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 5, 2008, Pages 683-688

  Beatty, Gregory L ^a   Giantonio, Bruce J ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE   (United States)

Author keywords

Advanced colorectal cancer; Angiogenesis; Bevacizumab; Chemotherapy; Metastatic; Oxaliplatin; Vascular endothelial growth factor; VEGF

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING DISORDER; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DNA SYNTHESIS INHIBITION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HYPERTENSION; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; REVIEW; SOLID TUMOR; VENOUS THROMBOEMBOLISM; BLOOD; COLORECTAL TUMOR; DRUG ANTAGONISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45849106868     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.5.683     Document Type: Review

References (46)

1. Wingo PA, Ries LA, Parker SL et al. Long-term cancer patient survival in the United States. Cancer Epidemiol. Biomarkers Prev. 7(4), 271-282 (1998).
2. Midgley R, Kerr D. Colorectal cancer. Lancet 353(9150), 391-399 (1999).
3. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
4. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000).
6. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20(21), 4368-4380 (2002).
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003).
8. Dirix LY, Vermeulen PB, Hubens G et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colofectal cancer. Ann. Oncol. 7(8), 843-848 (1996).
9. Berkman RA, Merrill MJ, Reinhold MC et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91(1), 153-159 (1993).
10. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53(19), 4727-4735 (1993).
11. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/ vascular cndothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146(5), 1029-1039 (1995).
12. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423), 841-844 (1993).
13. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7(9), 987-989 (2001).
14. Teicher BA. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction). Cancer Metastasis Rev. 15(2), 247-272 (1996).
15. Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88(12), 1979-1986 (2003).
16. Dickson PV, Hamner JB, Sims TL et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res. 13(13), 3942-3950 (2007).
17. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10(2), 145-147 (2004).
18. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibpdy for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593-4599 (1997).
19. Melnyk O, Zimmerman M, Kim KJ et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J. Urol. 161(3), 960-963 (1999).
20. Borgstrom P, Gold DP, Hillan KJ et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 19(5B), 4203-4314 (1999).
21. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19(3), 843-850 (2001).
22. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 19(3), 851-856 (2001).
23. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99(16), 1232-1239 (2007).
24. Pizzolato JF, Minsky BD, Guillen J, Shia J, Gonen M, Saltz LB. Neoadjuvant combined clictnoradiation for uT3/4 rectal rectal cancer: a retrospective comparison of infusional versus bolus fluorouracil. Presented at: 2005 Gastrointestinal Cancers Symposium. (2005) (Abstract 248).
25. Abdal Raheem S. Complications and effectiveness of combination chemotherapy in metastatic colorectal cancer (MCRC) with unresected primary (UP). ASCO Meeting Abstracts. J. Clin. Oncol. 25(18 Suppl.), 14537 (2007).
26. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (IV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21(1), 60-65 (2003).
27. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-434 (2003).
28. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004).
29. Johnson DH, DeVore R, Kabbinavar F, Herbst R, Holmgren E, Novotny W. Carboplatin (C) + paditaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc. Am. Soc. Clin. Oncol. 20, (2001) (Abstract 1256).
30. Kabbinavar FF, Johnson D, Langmuir VK, Holmgren E, Bergsland E. Patterns of tumor progression during therapy with bevacizumab (BV) and chemotherapy (CT) for metastatic colorectal cancer (MCRC) and advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, (2001) (Abstract 1105).
31. DeVore R, Febrenbacher L, Herbst R et al. A randomized Phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol. 19, (2000) (Abstract 1896).
32. Shaye OS, Chang HM, Yang DY et al. Polymorphisms in angiogenesis related genes predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first fine 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). ASCO Meeting Abstracts. J. Clin. Oncol. 25(18 Suppl.), 10576 (2007).
33. Ince WL, Jubb AM, Holden SN et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl Cancer Inst 97(13), 981-989 (2005).
34. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leuoovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol. 21(11), 2059-2069 (2003).
35. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22(1), 23-30 (2004).
36. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000).
37. No authors listed. Efficacy ofintravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J. Clin. Oncol. 16(1), 301-308 (1998).
38. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343(13), 905-914 (2000).
39. Fyfe GA, H. Hurwitz, Fehrenbacher L et al. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. Proc. Am. Soc. Clin. Oncol. 22(14 Suppl.), (2004) (Abstract 3617).
40. Hecht J, Chidiac T, Mitchell E et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC). Proceedings of the 9th World Congress on Gastrointestinal Cancer. Ann. Oncol. 18, vii21 (2007) (Abstract O-0033).
41. Saltz L, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized Phase III trial in first-line metastatic colorectal cancer. ASCO Meeting Abstracts. J. Clin. Oncol. 25(18 Suppl.), 4028 (2007).
42. Giantonio BJ, Meropol NJ, Catalano PJ et al. Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bcvacizumab (BV) in combination with oxaliplatin-containing regimens: an analysis of two Phase III studies. ASCO Meeting Abstracts. J. Clin. Oncol. 25(18 Suppl.), 4073 (2007).
43. Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 91(3), 173-180 (2005).
44. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J. Clin. Oncol. 23(22), 4853-4855 (2005).
45. Gruenberger T, Tamandl D, Puhalla H et al. Bevacizumab plus XELOX as ncoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ASCO Meeting Abstract. J. Clin. Oncol. 25(18 Suppl.), 4064 (2007).
46. Ocean AJ, O'Brien K, Lee J et al. Phase II trial of FOLFOX6, bevacizumab and cetuximab in patients with Colorectal Cancer. ASCO Meeting Abstracts. J. Clin. Oncol. 25(18 Suppl.), 4075 (2007).